Crescendo Biologics wins in “Life Science Innovation” category at the Business Weekly Awards 2019


The “Life Science Innovation” award recognises “the organisation or individual who has done the most to further the cause of life science discovery for the benefit of human healthcare”.

Crescendo was recognized by the judging panel for a very successful year. The Company continued to build upon its highly productive multi-programme collaboration with Takeda, with two major technical milestones reached; Takeda also took an early licence to Humabodies directed to one of its oncology targets, validating Crescendo’s ability to deliver Humabody®-based therapeutic leads. In addition, Crescendo closed a $70m Series B in April 2018, attracting new top-tier investors from Europe and Asia. At the same time, the Company has formed a truly world class leadership team by hiring top-tier management and non-executive directors.

Dr Peter Pack, CEO of Crescendo Biologics commented:
“We are extremely proud to have been awarded ‘Life Science Innovation’ at the Business Weekly Awards last night. It’s great to be recognised amongst the globally prestigious innovation hub of Cambridge. This is a testament to how well our team works together enabling so much success over the past 12 months.”

The Business Weekly Awards were held on Wednesday 20 March at Queens’ College, Cambridge, to celebrate the innovation cluster in Cambridge and the East of England.

-Ends-
For more information, please contact:

Crescendo Biologics
Dr Peter Pack, CEO
+ 44 (0)1223 497140
info@cresendobiologics.com

For Media:
Instinctif Partners for Crescendo Biologics
Deborah Bell, Dr Christelle Kerouedan, Melanie Toyne-Sewell
+ 44 (0)20 7457 2020
crescendo@instinctif.com

About Crescendo Biologics
Crescendo Biologics is a biopharmaceutical company developing potent, truly differentiated Humabody® therapeutics in oncology with a focus on innovative targeted T-cell approaches.

Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel bispecific PSMA-targeted T-cell enhancer for the selective activation of tumour-specific T-cells exclusively within the tumour microenvironment, thereby avoiding systemic toxicity. This highly modular format can be re-configured to create a pipeline of multiple therapeutic candidates each treating a different cancer indication, by targeting any of a range of alternative tumour-specific markers.

The Company’s ability to develop multi-functional Humabody® therapeutics is based on its unique, patent protected, transgenic mouse platform generating 100% human VH domain building blocks (Humabody® Vh). These robust molecules can be configured to optimally engage therapeutic targets delivering novel biology and superior bio-distribution. This results in larger therapeutic windows compared to conventional IgG approaches.

Crescendo Biologics is pursuing novel Humabody®-based product opportunities, through in-house development and strategic partnerships, including multi-functional immuno-oncology modulators and Humabody® drug conjugates (HDCs), the next generation of ADCs. Humabody®-based formats can also be applied across a range of non-cancer indications.

Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital and Astellas.

For more information, please visit the website: www.cresendobiologics.com.